[1]
A. A. Khalafallah, B. Fernandopulle, and T. Brain, “Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia”, Mediterr J Hematol Infect Dis, vol. 2, no. 2, p. e2010012, May 2010.